Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study

Imagem de Miniatura
Arquivos
art_RICE_Prognostic_models_for_patients_with_brain_metastases_after_2018.PDF (1.22 MB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
RICE, Stephanie R.
BENTZEN, Soren M.
HANNA, Andrew
CHOI, Enid
BOGGS, Drexell H.
KWOK, Young
HYDER, Jalal
FEIGENBERG, Steven J.
REGINE, William F.
WOODWORTH, Graeme F.
Citação
JOURNAL OF NEURO-ONCOLOGY, v.140, n.2, p.341-349, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose/Objective(s)To compare the performance of five prognostic models [RTOG recursive partitioning analysis (RPA), Score Index for Radiosurgery in Brain Metastases (SIR), Barnholtz-Sloan-Kattan nomogram (BSKN), diagnosis-specific Graded Prognostic Assessment (dsGPA), and Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)] against actual survival in patients with brain metastases treated with SRS +/- WBRT.Materials/Methods100 consecutive patients treated with SRS +/- WBRT between January 2006 and July 2012 were retrospectively analyzed. Patients were binned according to 33 percentiles of the predicted survival distribution for the BSKN and dsGPA models to compare with LungmolGPA, RPA and SIR. Pearson's correlation coefficients between predicted and observed survival were estimated to quantify the proportion of variance in observed survival.ResultsMedian survival for the entire cohort was 13.5 months, with predicted vs actual MS by BSKN, SIR, dsGPA, RPA, adenocarcinoma Lung-molGPA, and nonadenocarcinoma Lung-molGPA was 3.8 vs 15.6 months, 7 vs 13.5 months, 9.4 vs 13.5 months, 10.3 vs 13.5 months, 13.7 vs 13.7 months, and 9.8 vs 9.7 months, respectively. The BSKN model and adenocarcinoma LungmolGPA created three groups with a statistically significantly different MS (p=0.002 and p=0.01, respectively).ConclusionAll models under-predicted MS and only the BSKN and Lung-molGPA model stratified patients into three risk groups with statistically significant actual MS. The prognostic groupings of the adenocarcinoma Lung-molGPA group was the best predictor of MS, and showed that we are making improvements in our prognostic ability by utilizing molecular information that is much more widely available in the current treatment era.
Palavras-chave
Brain metastases, Modeling, Stereotactic radiosurgery, Validation, Whole brain radiation
URI
https://observatorio.fm.usp.br/handle/OPI/29895
Referências
  1. Ahluwalia Manmeet S, 2014, F1000Prime Rep, V6, P114, DOI 10.12703/P6-114
  2. American Brain Tumor Association, 2016, MET BRAIN TUM, DOI 10.1002/1097-0142(19810215)47
  3. [Anonymous], 2011, IBM SPSS STAT WINDOW
  4. Barnholtz-Sloan JS, 2012, NEURO-ONCOLOGY, V14, P910, DOI 10.1093/neuonc/nos087
  5. Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
  6. Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
  7. Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839
  8. Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0
  9. Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195
  10. Golden DW, 2008, J NEUROSURG, V109, P77, DOI 10.3171/JNS/2008/109/12/S13
  11. Johung KL, 2016, J CLIN ONCOL, V34, P123, DOI 10.1200/JCO.2015.62.0138
  12. Kondziolka D, 2014, J NEUROSURG, V120, P24, DOI 10.3171/2013.9.JNS13788
  13. Li J, 2008, INT J RADIAT ONCOL, V71, P64, DOI 10.1016/j.ijrobp.2007.09.059
  14. Li J, 2007, J CLIN ONCOL, V25, P1260, DOI 10.1200/JCO.2006.09.2536
  15. Nieder C, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-10
  16. Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
  17. Rusthoven CG, 2016, J CLIN ONCOL, V34, P2814, DOI 10.1200/JCO.2016.67.2410
  18. Sperduto PW, 2017, INT J RADIAT ONCOL, V99, P812, DOI 10.1016/j.ijrobp.2017.06.2454
  19. Sperduto PW, 2017, INT J RADIAT ONCOL, V98, P1069, DOI 10.1016/j.ijrobp.2017.03.030
  20. Sperduto PW, 2017, JAMA ONCOL, V3, P827, DOI 10.1001/jamaoncol.2016.3834
  21. Sperduto PW, 2016, INT J RADIAT ONCOL, V96, P406, DOI 10.1016/j.ijrobp.2016.06.006
  22. Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025
  23. Venur VA, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.06.01
  24. Weltman E, 2000, INT J RADIAT ONCOL, V46, P1155, DOI 10.1016/S0360-3016(99)00549-0
  25. White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - ODS/03